Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: William L. Molair II who wrote (7069)	8/29/1998 3:30:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Accrual for Trauma P III was 298 as of Aug 25. To me this is a bit higher than I expected, as I had thought the previous rate was a bit slow. The target is 1,600 and it was expected to take two years to get there. Trauma is probably seasonal to some extent, Memorial Weekend, etc. They had 252 in the meningococcemia trial. Unless the DSMB recomends stopping the trial there is no reason to expect that XOMA would halt it on its' own. I had thought they might simply decide that they had sufficient data and that the cost of waiting for Dec. was not worth adding more patients when the existing data would already permit a decision either way by the FDA. Was wrong on that line of reasoning. I do not understand why MacCamant is so convinced there will be an early halt.